Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Debt to Equity (2018 - 2022)

Historic Debt to Equity for Lipocine (LPCN) over the last 5 years, with Q1 2022 value amounting to $0.03.

  • Lipocine's Debt to Equity fell 6897.88% to $0.03 in Q1 2022 from the same period last year, while for Mar 2022 it was $0.03, marking a year-over-year decrease of 6897.88%. This contributed to the annual value of $0.05 for FY2021, which is 8608.37% down from last year.
  • Per Lipocine's latest filing, its Debt to Equity stood at $0.03 for Q1 2022, which was down 6897.88% from $0.05 recorded in Q4 2021.
  • In the past 5 years, Lipocine's Debt to Equity ranged from a high of $1.14 in Q4 2019 and a low of $0.03 during Q1 2022
  • Its 5-year average for Debt to Equity is $0.58, with a median of $0.6 in 2018.
  • In the last 5 years, Lipocine's Debt to Equity surged by 2821.98% in 2020 and then tumbled by 8838.31% in 2021.
  • Over the past 5 years, Lipocine's Debt to Equity (Quarter) stood at $1.09 in 2018, then grew by 4.52% to $1.14 in 2019, then crashed by 67.95% to $0.36 in 2020, then tumbled by 86.08% to $0.05 in 2021, then plummeted by 31.08% to $0.03 in 2022.
  • Its last three reported values are $0.03 in Q1 2022, $0.05 for Q4 2021, and $0.1 during Q3 2021.